Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 5/20 | 0.38 |
| ▸ | PDE2A | O00408 | 6/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4087871 | 0.94 | AKT1 (0.43) | AKT1AKT2DRD2PDE2APOLB | |
| SCHEMBL14161397 | 0.87 | AKT1 (0.42) | AKT1AKT2DRD2PDE2ARORC | |
| SCHEMBL22996124 | 0.86 | PDE2A (0.40) | AKT1AKT2DRD2PDE2ARORC | |
| SCHEMBL13047444 | 0.86 | AKT1 (0.41) | AKT1AKT2DRD2PDE2ARORC | |
| SCHEMBL360875 | 0.86 | AKT1 (0.45) | AKT1AKT2DRD2PDE2ARORC | |
| SCHEMBL10167156 | 0.86 | DRD2 (0.51) | AKT1AKT2DRD2CNR1CNR2 | |
| SCHEMBL17040898 | 0.85 | SSTR4 (0.47) | AKT1AKT2POLBCNR1CNR2 | |
| SCHEMBL15524001 | 0.85 | POLB (0.41) | PDE2APOLBALDH1A1L3MBTL1SSTR4 | |
| SCHEMBL2191957 | 0.84 | MAPT (0.46) | AKT1AKT2DRD2PDE2ACNR1 | |
| SCHEMBL4549959 | 0.84 | AKT1 (0.41) | AKT1AKT2DRD2PDE2ARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3122748-B1 | PROCESS OF PREPARING 3-(3-(4-(1-AMINOCYCLOBUTYL)PHENYL)-5-PHENYL-3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)PYRIDIN-2-AMINE | ARQULE INC (US) | 2018-09-26 | — | — | EP | claimed |
| WO-2025049326-A1 | TRICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| EP-4223754-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-09 | — | — | EP | disclosed |
| EP-4223754-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-09 | — | — | EP | disclosed |
| EP-3694502-B1 | NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3189036-B1 | COMPOSITIONS AND METHODS FOR TREATING PROLIFERATION DISORDERS | ARQULE INC (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-3189036-B1 | COMPOSITIONS AND METHODS FOR TREATING PROLIFERATION DISORDERS | ARQULE INC (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2012177844-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012177852-A1 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS | ARQULE, INC (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20120329791-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ArQuele, Inc. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120329793-A1 | Substituted Imidazopyridinyl Compounds | ARQULE, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120329793-A1 | Substituted Imidazopyridinyl Compounds | ARQULE, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| CN-102781940-A | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE INC | 2012-11-14 | — | — | CN | disclosed |
| US-20110288090-A1 | Inhibitors of AKT Activity | MERCK SHARP & DOHME CORP. | 2011-11-24 | — | — | US | disclosed |
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2011082270-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE. INC. (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | AKT2, MTOR, AKT1 | AKT1 3/4885AKT2 1/4885DRD2 4675/4885 |
| US-20120329791-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | MKI67, CDK4, ABL1 | AKT1 2285/4885AKT2 1216/4885DRD2 1821/4885 |
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | MKI67, CDK4, ABL1 | AKT1 2285/4885AKT2 1216/4885DRD2 1821/4885 |
| US-20110288090-A1 | Inhibitors of AKT Activity | PIK3CD, PIK3CA, PIK3CG | AKT1 9/4885AKT2 5/4885DRD2 4566/4885 |
| US-20120329793-A1 | Substituted Imidazopyridinyl Compounds | MKI67, CDK4, TP53 | AKT1 1882/4885AKT2 824/4885DRD2 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.